The Food and Drug Administration (FDA) has announced that seven more metered dose inhalers (MDIs) containing ozone-depleting propellants will be phased out. 

Four of the medications have already been discontinued: Tilade, Intal, Azmacort and Alupent; and two of the remaining three have a small market share: Aerobid and MaxAir. Combivent is used by patients with chronic obstructive pulmonary disease (COPD) and by some patients who have both COPD and asthma. 

The phase-out dates for each of these can be read here: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm208302.htm. [^] 

We expect that an Aerobid HFA replacement will be approved prior to its phase-out. We expect the same for Combivent. 

Visit our website, http://www.aanma.org, for more news and updates from AANMA. Thank you.

Related posts:

No Related posts yet